Pharmion Boosts Oncology Pipeline With Cabrellis Acquisition
This article was originally published in The Pink Sheet Daily
Executive Summary
Purchase gives Pharmion North American and EU rights to the novel anthracycline amrubicin, currently marketed in Japan for both small and non-small cell lung cancers.
You may also be interested in...
Vidaza Key To Celgene’s $2.9 Billion Pharmion Purchase
Celgene gains first myelodysplastic syndromes therapy to show survival benefit in high-risk patients, as well as full control of multiple myeloma therapy thalidomide and late-stage candidates.
Vidaza Key To Celgene’s $2.9 Billion Pharmion Purchase
Celgene gains first myelodysplastic syndromes therapy to show survival benefit in high-risk patients, as well as full control of multiple myeloma therapy thalidomide and late-stage candidates.
GPC Aims To Complete Satraplatin NDA In January, Despite Arbitration With Licensor Spectrum
Spectrum is seeking $12 million GPC was paid by sublicensee Pharmion.